drugset / Trial / NCT04930627
Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia
Phase 2
Unknown
20 enrolled
Children's Memorial Health Institute, Poland
Department of Internal Medicine, Hypertension and Vascular Diseases, The Medical University of Warsaw · collab
NaSingle-groupOpen-labelTreatment
Summary
Treatment of neutropenia of Glycogenosis type 1b patients with empagliflozin
Timeline
- Start
- 2021-07
- Primary completion
- 2024-06
- Completion
- 2025-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | 5 mg | Oral |
| Subject | Empagliflozin | Small molecule | 10 mg | Oral |